Guardian Pharmacy Services (GRDN) Expected to Announce Quarterly Earnings on Thursday

Guardian Pharmacy Services (NYSE:GRDN) is expected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.26 per share and revenue of $340.4490 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Guardian Pharmacy Services (NYSE:GRDN) last released its earnings results on Wednesday, May 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.The firm had revenue of $336.60 million during the quarter, compared to analysts’ expectations of $329.89 million. During the same quarter in the prior year, the company earned $0.22 EPS. The company’s revenue was up 2.2% on a year-over-year basis. On average, analysts expect Guardian Pharmacy Services to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Guardian Pharmacy Services Price Performance

GRDN opened at $40.81 on Thursday. The business’s 50-day moving average price is $40.64 and its two-hundred day moving average price is $36.61. Guardian Pharmacy Services has a 1 year low of $19.30 and a 1 year high of $44.00. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 49.17, a P/E/G ratio of 2.75 and a beta of 0.05.

Wall Street Analysts Forecast Growth

GRDN has been the subject of a number of research reports. Weiss Ratings downgraded Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Zacks Research cut Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Truist Financial upped their price target on Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Oppenheimer lifted their price objective on shares of Guardian Pharmacy Services from $38.00 to $43.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, Wall Street Zen lowered shares of Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Guardian Pharmacy Services currently has a consensus rating of “Moderate Buy” and an average price target of $42.83.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GRDN. Invesco Ltd. grew its stake in Guardian Pharmacy Services by 35.6% in the fourth quarter. Invesco Ltd. now owns 14,175 shares of the company’s stock valued at $427,000 after purchasing an additional 3,718 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Guardian Pharmacy Services during the 4th quarter worth approximately $348,000. Valiant Capital Management L.P. boosted its holdings in shares of Guardian Pharmacy Services by 15.8% in the 4th quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock valued at $37,085,000 after buying an additional 167,741 shares during the last quarter. Susquehanna Portfolio Strategies LLC acquired a new stake in shares of Guardian Pharmacy Services in the 4th quarter valued at approximately $333,000. Finally, Occudo Quantitative Strategies LP grew its stake in shares of Guardian Pharmacy Services by 94.8% in the fourth quarter. Occudo Quantitative Strategies LP now owns 31,266 shares of the company’s stock valued at $941,000 after buying an additional 15,218 shares in the last quarter.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.